Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of intravenous prostaglandin E1 (alprostadil) for non-arteritic anterior ischemic optic neuropathy
2017-004982-28Phase 2Terminated
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Alprostadil intravenous infusion with Placebo intravenous infusion (2 arms). Primary endpoint: Efficacy assessment. Started Mar 2018; status: terminated.
02
Drugs
Vasostenoon
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2017-004982-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004982-28.